Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Nkarta, Inc. (NKTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..." |
|
| 03/16/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer SOUTH SAN FRANCISCO, Calif., January 9, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the development and execution of Nkarta’s clinical strategy using off-the-shelf NK cell therapeutics since he joined our organization,” said Paul J. Hastings, President and CEO of Nkarta. “His expertise in the biology and engineering of NK cells, clinical develo..." |
|
| 12/05/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"13,333,334 Shares of Common Stock NKARTA, INC. Common Stock UNDERWRITING AGREEMENT April 25, 2022 Cowen and Company, LLC SVB Securities LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC New York, New York 10022 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055" |
|
| 04/25/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 04/22/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/29/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif. – Mar. 29, 2022 – Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced today the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors. “The speed of manufacturing innovation in cell and gene therapies in recent years has accelerated significantly. Angela is one of a handful of people who have been at the center of this activity,” said Paul J. Hastings, President and CEO of Nkarta. “Her expertise and insight in technical operations, supply..." |
|
| 03/17/2022 |
8-K
| Quarterly results|
Docs:
|
"Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights • On track to announce initial Phase 1 clinical trial data from two co-lead programs in 2022 – 1H 2022 - NKX101, a CAR NK cell therapy candidate engineered with NKG2D receptor, in relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome – FY 2022 - NKX019, a CAR NK cell therapy candidate engineered with CD19 receptor, in relapsed/refractory B cell malignancies SOUTH SAN FRANCISCO, Calif., March 17, 2022 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a year of solid execution for ..." |
|
| 11/10/2021 |
8-K
| Quarterly results |
| 10/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/07/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/12/2021 |
8-K
| Quarterly results |
| 07/14/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 06/15/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/13/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 04/28/2021 |
8-K
| Quarterly results |
| 03/25/2021 |
8-K
| Quarterly results |
| 01/19/2021 |
8-K
| Quarterly results |
| 01/13/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Cash and Cash Equivalents: As of September 30, 2020, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $330.2 million, which includes proceeds from the Company’s July 2020 IPO of $265.1 million, net of underwriting discounts and commissions and other offering costs. • R&D Expenses: Research & development expenses were $9.8 million for the third quarter of 2020, which includes $0.7 million of non-cash stock-based compensation expense. • G&A Expenses: General and administrative expenses were $3.9 million for the third quarter of 2020, which includes $0.9 million of non-cash stock-based compensation expense. • Net Loss. Net loss was $13.7 million, or $0.44 per basic and diluted share, for the quarter ended September 30, 2020. Financial Guida...",
"Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D‑Based NK Cell Cancer Immunotherapy NKX101" |
|
| 10/05/2020 |
8-K
| Quarterly results |
| 08/20/2020 |
8-K
| Quarterly results |
| 07/14/2020 |
8-K
| Quarterly results |
|
|